Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients.

Cancer chemotherapy and pharmacology - 1 Jan 2014

Hong Jung Yong, Nam Eun Mi, Lee Jeeyun, Park Joon Oh, Lee Sang-Cheol, Song Seo-Young, Choi Seong Ho, Heo Jin Seok, Park Se Hoon, Lim Ho Yeong, Kang Won Ki, Park Young Suk

Abstract excerpt

BACKGROUND: Statins have potential antineoplastic properties via arrest of cell-cycle progression and induction of apoptosis. A previous study demonstrated in vitro and in vivo antineoplastic synergism between statins and gemcitabine. The present randomized, double-blinded, phase II trial compared the efficacy and safety of gemcitabine plus simvastatin (GS) with those of gemcitabine plus placebo (GP) in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Gemcitabine

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Pancreatic Neoplasms

Share to ras Proteins

Share to Simvastatin

Source

Identifiers

PMID: 24162380
DOI: 10.1007/s00280-013-2328-1

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients.PMID 24162380Read ↗

Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancerSemantic proximity Read ↗

Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer.Semantic proximity Read ↗

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells.Semantic proximity Read ↗

A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Low-dose simvastatin protects pancreatic cancer cells by promoting mitochondrial autophagy through TFEBSemantic proximity Read ↗

Simvastatin induces G <sub>1</sub> arrest by up‐regulating GSK3β and down‐regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cellsSemantic proximity Read ↗

A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.Semantic proximity Read ↗

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances the Antitumoral Activity of Gemcitabine in Human Pancreatic Cancer Cell LinesSemantic proximity Read ↗

Variability in statin-induced changes in gene expression profiles of pancreatic cancerSemantic proximity Read ↗

The role of statins as therapeutic agents in cancerSemantic proximity Read ↗

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.Semantic proximity Read ↗

Calcitriol enhances gemcitabine antitumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model systemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.